

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

December 2013

Vol. 41, No. 12

CONTENTS

SPECIAL SECTION ON PREDICTION OF HUMAN PHARMACOKINETIC PARAMETERS FROM IN VITRO SYSTEMS

- Prediction of Human Pharmacokinetics in 2013 and Beyond. *J. Brian Houston* **1973**
- A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. *Li Di, Bo Feng, Theunis C. Goosen, Yurong Lai, Stefanus J. Steyn, Manthana V. Varma, and R. Scott Obach* **1975**
- Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. *Carole E. Shardlow, Grant T. Generaux, Aarti H. Patel, Guoying Tai, Thuy Tran, and Jackie C. Bloomer* **1994**
- CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling. *Cong Xu, Sara K. Quinney, Yingying Guo, Stephen D. Hall, Lang Li, and Zeruesenay Desta* **2004**
- In Vitro P-glycoprotein Efflux Ratio Can Predict the In Vivo Brain Penetration Regardless of Biopharmaceutics Drug Disposition Classification System Class. *Ryota Kikuchi, Sonia M. de Moraes, and J. Cory Kalvass* **2012**
- In Vitro–In Vivo Correlation for Low-Clearance Compounds Using Hepatocyte Relay Method. *Li Di, Karen Atkinson, Christine C. Orozco, Carrie Funk, Hui Zhang, Thomas S. McDonald, Beijing Tan, Jian Lin, Cheng Chang, and R. Scott Obach* **2018**
- Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. *Tom S. Chan, Hongbin Yu, Amanda Moore, Salman R. Khetani, and Donald Tweedie* . . **2024**
- Utility of In Vitro Systems and Preclinical Data for the Prediction of Human Intestinal First-Pass Metabolism during Drug Discovery and Preclinical Development. *Fredrik H. Karlsson, Salim Bouchene, Constanze Hilgendorf, Hugues Dolgos, and Sheila Annie Peters* **2033**
- Drug Metabolites as Cytochrome P450 Inhibitors: A Retrospective Analysis and Proposed Algorithm for Evaluation of the Pharmacokinetic Interaction Potential of Metabolites in Drug Discovery and Development. *Ernesto Callegari, Amit S. Kalgutkar, Louis Leung, R. Scott Obach, David R. Plowchalk, and Susanna Tse* **2047**
- Stereoselective Inhibition of CYP2C19 and CYP3A4 by Fluoxetine and Its Metabolite: Implications for Risk Assessment of Multiple Time-Dependent Inhibitor Systems. *Justin D. Lutz, Brooke M. VandenBrink, Katipudi N. Babu, Wendel L. Nelson, Kent L. Kunze, and Nina Isoherranen* **2056**
- Heterotropic Activation of the Midazolam Hydroxylase Activity of CYP3A by a Positive Allosteric Modulator of mGlu₅: In Vitro to In Vivo Translation and Potential Impact on Clinically Relevant Drug-Drug Interactions. *Anna L. Blobaum, Thomas M. Bridges, Frank W. Byers, Mark L. Turlington, Margrith E. Mattmann, Ryan D. Morrison, Claire Mackie, Hilde Lavreysen, José M. Bartolomé, Gregor J. MacDonald, Thomas Steckler, Carrie K. Jones, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley, Shaun R. Stauffer, and J. Scott Daniels* **2066**

SHORT COMMUNICATION

- Targeted Precise Quantification of 12 Human Recombinant Uridine-Diphosphate Glucuronosyl Transferase 1A and 2B Isoforms Using Nano-Ultra-High-Performance Liquid Chromatography/Tandem Mass Spectrometry with Selected Reaction Monitoring. *John K. Fallon, Hendrik Neubert, Theunis C. Goosen, and Philip C. Smith* **2076**

ARTICLES

- N-Acetylation of Etamicastat, a Reversible Dopamine- β -Hydroxylase Inhibitor. *Ana I. Loureiro, Carlos Fernandes-Lopes, Maria João Bonifácio, Lyndon C. Wright, and Patrício Soares-da-Silva* . . **2081**

Continued on next page

- ☐ Activity, Inhibition, and Induction of Cytochrome P450 2J2 in Adult Human Primary Cardiomyocytes. *Eric A. Evangelista, Rüdiger Kaspera, Nahush A. Mokadam, J. P. Jones, III, and Rheem A. Totah* **2087**
- ☐ Assessment of Vandetanib as an Inhibitor of Various Human Renal Transporters: Inhibition of Multi-drug and Toxin Extrusion as a Possible Mechanism Leading to Decreased Cisplatin and Creatinine Clearance. *Hong Shen, Zheng Yang, Weiping Zhao, Yueping Zhang, and A. David Rodrigues* **2095**
- Learning and Confirming with Preclinical Studies: Modeling and Simulation in the Discovery of GDC-0917, an Inhibitor of Apoptosis Proteins Antagonist. *Harvey Wong, Stephen E. Gould, Nageshwar Budha, Walter C. Darbonne, Edward E. Kadel III, Hank La, Bruno Aliche, Jason S. Halladay, Rebecca Erickson, Chia Portera, Anthony W. Tolcher, Jeffery R. Infante, Michael Mamounas, John A. Flygare, Cornelis E. C. A. Hop, and Wayne J. Fairbrother* **2104**
- Characterization of Inhibition Kinetics of (S)-Warfarin Hydroxylation by Noscaphine: Implications in Warfarin Therapy. *Nan Zhang, Ryan P. Seguin, Kent L. Kunze, Yan-Yan Zhang, and Hyunyoung Jeong* **2114**
- Characterization of Transplacental Transfer of Paroxetine in Perfused Human Placenta: Development of a Pharmacokinetic Model to Evaluate Tapered Dosing. *Marie Nagai, Hisakazu Ohtani, Hiroki Satoh, Sayo Matsuoka, Satoko Hori, Tomoyuki Fujii, Yuji Taketani, and Yasufumi Sawada* **2124**
- ☐ Metabolism and Excretion of 6-Chloro-9-(4-methoxy-3,5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 Inhibitor, in Rats and Dogs and Assessment of Its Metabolic Profile in Plasma of Humans. *Lin Xu, Caroline Woodward, Jing Dai, and Chandra Prakash* **2133**
- ☐ In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)-Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes. *Raman Sharma, Thomas S. McDonald, Heather Eng, Chris Limberakis, Benjamin D. Stevens, Sheena Patel, and Amit S. Kalgutkar* . . **2148**
- Assessment of the Roles of P-glycoprotein and Cytochrome P450 in Triptolide-induced Liver Toxicity in Sandwich-Cultured Rat Hepatocyte Model. *Xiao-Mei Zhuang, Guo-Lin Shen, Wei-Bin Xiao, Yan Tan, Chuang Lu, and Hua Li* **2158**
- Cytochrome P4503A Does Not Mediate the Interaction between Methadone and Ritonavir-Lopinavir. *Evan D. Kharasch and Kristi Stubbert* **2166**
- ☐ RNA-Sequencing Quantification of Hepatic Ontogeny of Phase-I Enzymes in Mice. *Lai Peng, Julia Y. Cui, Byunggil Yoo, Sumedha S. Gunewardena, Hong Lu, Curtis D. Klaassen, and Xiao-bo Zhong* . . . **2175**
- ☐ Two Polymorphic Variants of *ABCC1* Selectively Alter Drug Resistance and Inhibitor Sensitivity of the Multidrug and Organic Anion Transporter Multidrug Resistance Protein 1. *Gwenaëlle Conseil and Susan P.C. Cole* **2187**
- ☐ Modulation of the UGT2B7 Enzyme Activity by C-Ternally Truncated Proteins Derived from Alternative Splicing. *Vincent Ménard, Pierre Collin, Guillaume Margailan, and Chantal Guillemette* . . **2197**
- Lymphatic Absorption, Metabolism, and Excretion of a Therapeutic Peptide in Dogs and Rats. *Yan Zou, Thomas J. Bateman, Christine Adreani, Xiaolan Shen, Paul K. Cunningham, Bo Wang, Tu Trinh, Amy Christine, Xuening Hong, Christian N. Nunes, Chris V. Johnson, Andy S. Zhang, Steve J. Staskiewicz, Matthew Braun, Sanjeev Kumar, and Vijay Bhasker G. Reddy* **2206**
- ☐ Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation. *David A. Bershas, Daniele Ouellet, Donna B. Mamaril-Fishman, Noelia Nebot, Stanley W. Carson, Samuel C. Blackman, Royce A. Morrison, Jerry L. Adams, Kristen E. Jurusik, Dana M. Knecht, Peter D. Gorycki, and Lauren E. Richards-Peterson* . . . **2215**
- ☐ Effect of Gestational Age on mRNA and Protein Expression of Polyspecific Organic Cation Transporters during Pregnancy. *Nora Lee, Mary F. Hebert, Bhagwat Prasad, Thomas R. Easterling, Edward J. Kelly, Jashvant D. Unadkat, and Joanne Wang* . . . **2225**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Simulation of the fold difference in prediction magnitude that would occur using the additive model instead of the inhibitor-inhibitor interaction model as a function of in vivo inhibitor potency. See article by Lutz et al. on page 2056 of this issue.